Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)

Next Previous
X
Search
Trial Profile

Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 11 Nov 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Belinostat (Primary) ; Cyclophosphamide (Primary) ; Doxorubicin (Primary) ; Prednisone (Primary) ; Vincristine (Primary)
  • Indications Peripheral T-cell lymphoma
  • Focus Adverse reactions
  • Sponsors Spectrum Pharmaceuticals

    • Most Recent Events

    • 26 Apr 2021 According to an Acrotech Biopharma media release, Patrick B Johnston, (MD, PhD of the Mayo Clinic) is the lead investigator of this study.
    • 26 Apr 2021 According to an Acrotech Biopharma media release, data from this phase 1 study, were published in the journal Experimental Hematology and Oncology.
    • 26 Apr 2021 Results presented in an Acrotech Biopharma media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top